By: Kairos Ventures On: January 3, 2018 In: Portfolio News, Symbiotix

We are pleased to announce that our portfolio company Symbiotix Biotherapies, Inc. has entered into a process development and manufacturing agreement with Paragon Bioservices, Inc., a global leader in the manufacturing of complex biopharmaceuticals.

“Paragon Bioservices has a proven track record in biopharmaceutical process development and is known for transitioning from the research bench to manufacturing of finished drug product for clinical use.”
– Nader Yaghoubi, M.D., Ph.D., President and Chief Executive Officer of Symbiotix

According to the agreement, Paragon will continue its work on Symbiotix’s lead program to complete the optimization of the downstream production process for SYMB-104 in preparation for production of clinical material at scale. The process development work will utilize Symbiotix’s proprietary engineered production strain of B. fragilis, a strain engineered to overexpress a specific immunomodulatory polysaccharide without production of other capsular polysaccharides typically produced by this organism. SYMB-104 is a ReglemerTM based on a specific capsular polysaccharide produced by B. fragilis that is capable of modulating regulatory T cell activity, and is protected by issued composition-of-matter patents. Terms of the manufacturing agreement were not disclosed.

“Paragon Bioservices has a proven track record in biopharmaceutical process development and is known for transitioning from the research bench to manufacturing of finished drug product for clinical use,” said Nader Yaghoubi, M.D., Ph.D., President and Chief Executive Officer of Symbiotix. “As we position Symbiotix for commencing human clinical trials, this agreement enables us to operationally leverage Paragon’s expertise while we seek to advance SYMB-104 for treatment of immune-mediated diseases.”

“We are pleased that Symbiotix Biotherapies has chosen Paragon Bioservices as their process development and manufacturing partner and believe that it is testament to the value that our scientific expertise brings to a program,” said Peter Buzy, Chief Executive Officer of Paragon. “We look forward to having our best-in-class development and manufacturing teams continue to work closely with the Symbiotix team to advance their first-in-class programs from development into the clinic.”

Congratulations to the Symbiotix team!

Print Friendly, PDF & Email